Fund moves
89KShares reported
2 tracked managers disclosed the same change for Q3 2026. From a 13F filed Nov 16, 2026 covering holdings at Sep 30, 2026 — a quarter-end snapshot, not a live trade.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
RGEN · NASDAQ · Biotechnology
Repligen (RGEN) · oqro.io/stocks/RGEN · printed today. Every figure comes from a public filing, linked on the page online. Not investment advice.
$163.81−6.48 (−3.81%)
Close of Nov 20, 2026, vs Nov 19 · end-of-day
No open-market purchase by an insider of Repligen was filed in the last 90 days. The latest on record was on Aug 12, 2025.
Since 2003, Repligen insiders reported 33 open-market purchases and 487 sales on Forms 4 and 5, with purchases in 13 different years, most recently 2025.
In the last 90 days, 1 insider of Repligen (RGEN) reported 6 open-market sales worth $4.98M in total on SEC Form 4. The largest seller by value was Olivier Loeillot, with $4.98M. Many insider sales follow a plan set in advance or cover taxes on stock awards; the filing says what was sold, not the reason.
Yes. Members of Congress disclosed 3 trades in Repligen (RGEN) in the last 12 months, each reported as a value range on a periodic transaction report. The most recent is from Rep. Lisa C. McClain (MI09).
Repligen's next results are expected on Feb 22, 2027, before the market opens. The date can move until the company confirms it. Insiders often trade in the weeks right after results.
From official filings only: SEC Forms 4, 5 and 144 for insiders, House and Senate periodic transaction reports for Congress, SEC Form 13F for funds, Form 8-K for company events and USAspending for federal contracts. Every record on OQRO links to its source. It is public data, not investment advice.
+6.1% (+$9.45) from Nov 20, 2025 to Nov 20, 2026 · adjusted daily closes
Adjusted close went from $154.36 on Nov 20, 2025 to $163.81 on Nov 20, 2026 (+6.1%). Disclosed in this range: 1 insider trade, 11 pre-arranged insider sales, 0 Congress trades, and 48 13F position changes for 4 quarters ending in it.
Counts of filings OQRO holds, by the date each was filed or the award started. Every figure links to its official SEC, House, Senate or USAspending record.
Biotechnology company based in Waltham, Massachusetts.
Last 12 months
+6.1%
Market value
$10.5B
S&P 500 +5.7% over the same dates. Prices adjusted for splits and dividends.
Short interest: 7.05M shares sold short (11.0% of shares outstanding), −1.3% vs the previous count, 4.9 days of normal trading to buy them back. FINRA, as of Oct 30, 2026.
Revenue
$209M
+10.9% vs the same quarter a year earlier
Free cash flow, last 12 months
$107M
This quarter $38.2M, a year earlier $43.4M
Net cash
$171M
Debt $556M, cash $727M, at Sep 30, 2026
Net income, last 12 months
−$11.8M
Operating profit covers interest 0.812x
From the company's own quarterly and annual reports to the SEC. Free cash flow (cash from operations minus capital spending), net debt (debt minus cash) and 12-month totals are calculated by OQRO. Production rates, deliveries, approvals and guidance are in its results announcement of Oct 27, 2026.
Revenue, fiscal 2025
$738M
+16.4% vs the year before
Net income, fiscal 2025
$48.9M
As reported in the annual filing
Shares outstanding
63.9M
As of Oct 23, 2026
New federal contracts from the last 12 months add up to 0.05% of that revenue. Contract money is usually earned over several years, so this is a size comparison, not a share of sales.
Fund moves
2 tracked managers disclosed the same change for Q3 2026. From a 13F filed Nov 16, 2026 covering holdings at Sep 30, 2026 — a quarter-end snapshot, not a live trade.
Fund moves
2 tracked managers disclosed the same change for Q3 2026. From a 13F filed Nov 16, 2026 covering holdings at Sep 30, 2026 — a quarter-end snapshot, not a live trade.
Loeillot Olivier (Officer) plans to sell ~$798K of Repligen
Planned, from payPrices are daily closes from Polygon.io. Company figures come from its own SEC filings. Past moves are not a forecast. OQRO reports what was filed and never tells you what to buy or sell.
Against the S&P 500 over the year
Since Nov 19, 2025, RGEN is up 5.6% and the index fund is up 4.1%: 2 points ahead of the market. Traders call a stock that beats the index over a period a relative-strength leader.
How much RGEN moves
Beta 1.2 (1 year vs SPY)
End-of-day prices. These figures describe the past year and say nothing about what comes next. Beta: how much the stock moved, on average, for each 1% move of the S&P 500 fund over 251 trading days (1 = in step with it).
Source: SEC Schedules 13D and 13G, which anyone owning more than 5% of a class of stock must file. A 13D filer may seek to influence the company; a 13G filer is passive. Filings before December 2024 are free text and read from their cover page: a percent or share count that is not stated plainly is left blank. Each line links to the filing.
Insiders of Repligen reported 33 open-market purchases and 487 sales since 2003; purchases in 13 different years, most recently 2025.
| Year | Bought | Sold |
|---|---|---|
| 2026 | — | $6.68M10×10 trades |
| 2025 | $240K2×2 trades | $19.4M32×32 trades |
| 2024 | $600K4×4 trades | $16.9M25×25 trades |
| 2023 | $238K3×3 trades | $1.83M3×3 trades |
| 2022 | $109K1×1 trade | $23.3M25×25 trades |
| 2021 | — | $40.3M120×120 trades |
| 2020 | — | $35.7M81×81 trades |
| 2019 | — | $4.58M24×24 trades |
| 2018 | — | $26.4M23×23 trades |
| 2017 | — | $1.16M6×6 trades |
| 2016 | — | $710K5×5 trades |
| 2015 | — | $12.2M13×13 trades |
| 2014 | $107K2×2 trades | $7.14M14×14 trades |
| 2013 | $7.7K1×1 trade | $1.82M18×18 trades |
| 2012 | $71K6×6 trades | $554K19×19 trades |
| 2011 | $154K8×8 trades | — |
| 2009 | $25K1×1 trade | $2.49M4×4 trades |
| 2008 | $7K1×1 trade | $155K22×22 trades |
| 2007 | — | $764K28×28 trades |
| 2006 | $6.7K1×1 trade | $721K14×14 trades |
| 2005 | $11K2×2 trades | $28K1×1 trade |
| 2003 | $5K1×1 trade | — |
Open-market purchases (code P) and sales (code S) on Forms 4 and 5. Up to Sep 2024 from the SEC's Insider Transactions Data Sets; since Oct 2024 from each filing as it is published. A trade filed twice (an amendment) counts once. Dollar totals use the price the filer reported; lines with no price count as trades without a value.
Written by software from the filings listed below · Oct 26, 2026
3 more points, with the facts they come from, are in OQRO Pro.
Sign up freeLast results
Oct 27, 2026
Within the 30 days after it, until Nov 26, 2026
Next results, expected
Feb 22, 2027
before the market opens; the date can move until the company confirms it
Purchases after results
59%
16 of 27 insider purchases since 2010 came within 30 days after a results announcement
From Repligen's own results filings (8-K Item 2.02) and its insiders' Forms 4 and 5. Many companies only let insiders trade in a period after results; OQRO does not know Repligen's policy and only shows the pattern in the filings. A purchase made long after results, at a company whose insiders usually buy right after them, is marked “Bought outside the usual window”.
Top officer leaving
“With a successful CEO transition complete, I believe now is the right time for my retirement.”
1 insider sold ~$1.48M in the 60 days before
8-K on sec.govFrom the company's 8-K, 10-K and 10-Q filings over the last two years. A flag is a reason to read the filing, not a verdict: many departures are planned retirements and many listing notices are resolved. Insider sales are shown for timing only; they are separate filings.
Latest annual report filed Feb 26, 2026, compared with the one filed Mar 14, 2025. Read the filing
From time to time, we may be subject to legal proceedings and claims in the ordinary course of business. We are not currently aware of any such proceedings or claims that we believe will have, individually or in the aggregate, a material adverse effect on our business, financial condition or results of operations.
Source: SEC EDGAR, Form 10-K filed Feb 26, 2026. Headings are the titles the company gives each risk; OQRO compares them with the year before by their words, so a heading that was reworded a lot shows up as both new and no longer listed. Companies list the risks they face, not forecasts.
Off-exchange trading: 48.7% of the shares traded over the latest 4 published weeks changed hands away from the exchanges (30.2% on ATS, 18.5% with other brokers), above its 26-week average of 46.0%. Weeks of Oct 5 to Oct 30, 2026.
Largest ATS: UBS ATS (13.2%), SIGMA X2 (12.4%), INTELLIGENT CROSS LLC (11.6%), as a share of this stock's ATS volume over the same 4 weeks.
An ATS, often called a dark pool, is a private trading venue run by a broker where orders are not shown publicly before they trade. Other off-exchange trades are mostly retail orders filled by wholesale brokers. A high share is common and says nothing by itself about where the price goes. FINRA OTC Transparency data, published 2 weeks after each week for the largest stocks and 4 weeks for others; total volume from our daily price data.
Written by OQRO's software from the last 12 months on record · Nov 19, 2026
Every number, name, date and link in the text above comes from this list; software checks that before the text is stored. This text was assembled directly from the facts, without a language model.
Insiders
Congress
Funds and stakes
Contracts, lobbying and filings
Company reports, price and press
Who holds it
Deals
Things to keep in mind
1 certified in FY2026 Q3, vs 1 a year earlier. 1 position in total, median offered wage $162K a year.
Labor condition applications for H-1B workers certified by the Department of Labor, counted by decision date (FY2026 Q3: Apr 1, 2026 to Jun 30, 2026, the latest quarter published). A certified application is a step before a visa petition, not a hire or a visa, and one application can cover several positions. Matched by employer ID number or name.
Fiscal year Jan 1, 2025 to Dec 31, 2025, from the annual report filed Feb 26, 2026. Read the filing
+8.0% on the year before ($373M)
+25% on the year before ($123M)
+31% on the year before ($74.4M)
+37% on the year before ($59.3M)
−29% on the year before ($4.68M)
+13% on the year before ($261K)
The company also reports Product Revenue ($738M), which group lines above and are not added again.
Every annual report has a section where the company's managers explain the year's results (Item 7, Management's discussion and analysis). In this report it runs to about 6,000 words.
Information pertaining to fiscal years 2024 and 2023 was included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2024, on pages 39 through 52 under Part II, Item 7, “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” which was filed with the SEC on March 14, 2025. Repligen and its subsidiaries, collectively doing business as Repligen Corporation (“Repligen”, “we”, “our”, or “the Company”) is a global life sciences company that develops and commercializes highly innovated bioprocessing technologies and systems that increase efficiencies and flexibility in the process of manufacturing biological drugs.
Source: SEC EDGAR, Form 10-K filed Feb 26, 2026. Revenue lines are the figures the company tags in its filing; OQRO shows a split only when its lines add up to the reported total revenue. The quote is the opening of the managers' discussion, cut at a sentence; the word count is estimated from its length. Not investment advice.
And 21 more headings in the filing.